Kinnari Patel
President at ROCKET PHARMACEUTICALS, INC.
Net worth: 11 M $ as of 31/05/2024
Kinnari Patel active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Chief Operating Officer | 04/01/2018 | - |
| Chief Tech/Sci/R&D Officer | 27/03/2024 | - | |
| President | - | - |
Career history of Kinnari Patel
Former positions of Kinnari Patel
| Companies | Position | Start | End |
|---|---|---|---|
Rocket Pharmaceuticals Ltd.
 Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Chief Operating Officer | 01/01/2018 | 01/02/2021 |
| General Counsel | 01/04/2016 | 01/12/2017 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2010 | 01/04/2014 |
Training of Kinnari Patel
| The Leonard N Stern School of Business | Masters Business Admin |
| University of the Sciences in Philadelphia | Doctorate Degree |
Statistics
International
| United States | 6 |
Operational
| Chief Operating Officer | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| President | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 1 |
|---|---|
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Kinnari Patel
- Experience
